5 news items
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
LSTA
28 May 24
to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
LSTA
20 May 24
. Lisata has already established noteworthy commercial and R&D partnerships based on its
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
LSTA
2 May 24
commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
LSTA
23 Apr 24
therapeutics, 12 manufacturing sites and more than 36,000 employees worldwide, Qilu is dedicated to transforming scientific innovation by internal R&D across
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
LSTA
3 Apr 24
has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business
- Prev
- 1
- Next